1-[[[(1R)-1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid sodium salt hydrate
IDENTITY
CAS Number:
151767-02-1
MDL Number:
MFCD00931431
MF:
C35H35ClNNaO3S
MW:
608.17
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:
98% (HPLC)
Physical Form (at 20°C):
Solid
Melting Point:
84-90°C
Optical Rotation:
+95.0° - +105.0° (c=1, MeOH)
Long-Term Storage:
Store long-term at 2-8°C
DOT/IATA TRANSPORT INFORMATION
Not hazardous material
BIOLOGICAL INFO
Solubility:
DMSO: =8 mg/mL at 60 °C
Application(s):
Receptor antagonist (LTRA)
REVIEW Montelukast selectively antagonizes leukotriene D4 (LTD4) at the cysteinyl leukotriene receptor, CysLT1, in the human airway. Montelukast inhibits the actions of LTD4 at the CysLT1 receptor, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus.
These chemical products are for research and development use only. They are not for diagnostic, therapeutic, cosmetic, or human and animal uses. They are not sold to individuals. Additional restrictions may apply.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information.